PRF Technologies Files to Sell 7.5M Ordinary Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
PRF Technologies files to sell 7.5M ordinary shares for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRFX
About PRFX
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PRF Technologies Expands PRF-110 Study Results for Post-Operative Pain Management
- Efficacy Comparison: PRF-110 demonstrated comparable reductions in mechanical sensitivity to ZYNRELEF, indicating similar analgesic performance, thereby reinforcing confidence in PRF-110's application in post-operative pain management.
- Pharmacokinetic Advantage: PRF-110 exhibited a slower absorption rate compared to ZYNRELEF, suggesting a more gradual release of ropivacaine at the administration site, which may help prolong local analgesia and reduce reliance on opioids post-surgery.
- Enhanced Tissue Retention: PRF-110 showed increased retention in local tissue along with higher local tissue exposure (Cmax), supporting prolonged availability of the active compound at the target site, further enhancing its clinical application potential.
- Sustained Exposure Characteristics: Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions, aligning with PRF Technologies' strategic goals in post-operative pain management.
See More
PRF Technologies Launches DeepSolar Predict Platform for Renewable Energy Optimization
- Platform Functionality Upgrade: PRF Technologies' DeepSolar Predict platform integrates AI forecasting, storage intelligence, and market-driven decision support, aiming to enable renewable energy operators to achieve real-time revenue optimization, thereby enhancing overall operational efficiency and financial performance.
- Market Demand Response: As the renewable energy market rapidly evolves, DeepSolar Predict will assist asset owners and operators in addressing challenges such as weather variability and production uncertainty, ensuring higher asset value and market competitiveness.
- Technological Innovation Application: The platform builds on PRF's previous DeepSolar initiatives, leveraging support from the NVIDIA Connect program to implement patented plant-level micro-climate modeling, which enhances the accuracy of solar production forecasts and improves market adaptability.
- Strategic Market Positioning: PRF Technologies believes that the launch of DeepSolar Predict will position the company significantly within the global renewable energy asset management landscape, addressing the urgent market need for improved forecasting accuracy and margin protection.
See More
PRF Technologies Announces Positive Results for PRF-110 in Preclinical Study
- Preclinical Study Results: PRF Technologies' preclinical study shows that PRF-110 demonstrates comparable analgesic effects to ZYNRELEF over a 72-hour period, indicating its potential in postoperative pain management and providing crucial support for future product development.
- NSAID-Free Formula Advantage: The ropivacaine-only formulation of PRF-110 avoids NSAID use, and its lower cardiac toxicity may offer physicians a safer non-opioid pain relief option, potentially enhancing market acceptance.
- Rigorous Study Design: Conducted in a validated pig incisional pain model using von Frey methodology, the study ensures reliability and effectiveness of results, laying a solid foundation for subsequent clinical trials.
- Broad Market Prospects: With increasing healthcare system demands to reduce opioid reliance, the successful development and approval of PRF-110 could open new growth opportunities for PRF Technologies in the postoperative pain management market, enhancing its competitive edge.
See More
PRF Technologies Receives FDA Clearance for OcuRing™-K Clinical Trial
- FDA Milestone: PRF Technologies' OcuRing™-K has received IND clearance from the FDA, marking a significant advancement in the company's ophthalmic drug delivery strategy, with plans to initiate a multi-center Phase II clinical trial in the second half of 2026 to evaluate pain reduction and inflammation control.
- Innovative Treatment: OcuRing™-K is a bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application, potentially eliminating the need for complex post-surgical eye drop regimens, thereby simplifying patient recovery and improving treatment consistency.
- Addressing Market Needs: Cataract surgery is one of the most commonly performed procedures globally, and PRF Technologies' OcuRing™-K aims to enhance drug delivery consistency and reduce dosing burdens, which could significantly improve patient adherence to post-operative care.
- Strategic Platform Expansion: Through its majority ownership of LayerBio, PRF Technologies is building a differentiated ophthalmic platform that may support various applications, including other NSAIDs, steroids, and anti-VEGF products, thereby enhancing the company's long-term value proposition in the healthcare sector.
See More
PainReform Reports Significant Reduction in FY 2025 Net Loss
- Net Loss Reduction: PainReform reported a net loss of approximately $4.8 million for FY 2025, significantly down from $14.6 million in FY 2024, indicating positive progress in cost control and operational efficiency.
- Cash Position: As of December 31, 2025, PainReform held approximately $4.1 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operations and growth initiatives.
- Financial Income Growth: The financial income for FY 2025 was $108,000, up from approximately $93,000 in FY 2024, reflecting improvements in investment returns that may lay the groundwork for future profitability.
- Future Outlook: With the reduction in net loss and improved cash flow, PainReform is positioned for better financial performance in the future, enhancing investor confidence and supporting potential business expansion.
See More
PRF Technologies Partners with EDF for Solar Analytics Agreement
- Strategic Partnership: PRF Technologies' DeepSolar unit has signed a solar analytics services agreement with a subsidiary of EDF Group, marking a new phase for its utility-scale solar power plant in Israel and expected to create new commercial revenue opportunities for the company.
- Technical Due Diligence Initiated: Under the agreement, DeepSolar has commenced a technical due diligence engagement, analyzing historical and operational data to support an independent technical review of the solar asset, thereby enhancing transparency and decision-making efficiency in asset management.
- Smart TDD Service Implementation: DeepSolar's Smart TDD service is designed to support multiple use cases across the solar asset lifecycle through analytics-driven methodologies, helping clients identify potential defects and optimize asset performance during acquisition and performance assessments.
- Growing Market Demand: PRF Technologies' Chairman Ehud Geller noted that the increasing demand for technical due diligence and analytics services among large solar operators illustrates the growing commercial interest in DeepSolar's offerings, indicating significant growth potential for the company in the renewable energy sector.
See More
PRF Technologies Expands PRF-110 Study Results for Post-Operative Pain Management
- Efficacy Comparison: PRF-110 demonstrated comparable reductions in mechanical sensitivity to ZYNRELEF, indicating similar analgesic performance, thereby reinforcing confidence in PRF-110's application in post-operative pain management.
- Pharmacokinetic Advantage: PRF-110 exhibited a slower absorption rate compared to ZYNRELEF, suggesting a more gradual release of ropivacaine at the administration site, which may help prolong local analgesia and reduce reliance on opioids post-surgery.
- Enhanced Tissue Retention: PRF-110 showed increased retention in local tissue along with higher local tissue exposure (Cmax), supporting prolonged availability of the active compound at the target site, further enhancing its clinical application potential.
- Sustained Exposure Characteristics: Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions, aligning with PRF Technologies' strategic goals in post-operative pain management.
See More
PRF Technologies Launches DeepSolar Predict Platform for Renewable Energy Optimization
- Platform Functionality Upgrade: PRF Technologies' DeepSolar Predict platform integrates AI forecasting, storage intelligence, and market-driven decision support, aiming to enable renewable energy operators to achieve real-time revenue optimization, thereby enhancing overall operational efficiency and financial performance.
- Market Demand Response: As the renewable energy market rapidly evolves, DeepSolar Predict will assist asset owners and operators in addressing challenges such as weather variability and production uncertainty, ensuring higher asset value and market competitiveness.
- Technological Innovation Application: The platform builds on PRF's previous DeepSolar initiatives, leveraging support from the NVIDIA Connect program to implement patented plant-level micro-climate modeling, which enhances the accuracy of solar production forecasts and improves market adaptability.
- Strategic Market Positioning: PRF Technologies believes that the launch of DeepSolar Predict will position the company significantly within the global renewable energy asset management landscape, addressing the urgent market need for improved forecasting accuracy and margin protection.
See More
PRF Technologies Announces Positive Results for PRF-110 in Preclinical Study
- Preclinical Study Results: PRF Technologies' preclinical study shows that PRF-110 demonstrates comparable analgesic effects to ZYNRELEF over a 72-hour period, indicating its potential in postoperative pain management and providing crucial support for future product development.
- NSAID-Free Formula Advantage: The ropivacaine-only formulation of PRF-110 avoids NSAID use, and its lower cardiac toxicity may offer physicians a safer non-opioid pain relief option, potentially enhancing market acceptance.
- Rigorous Study Design: Conducted in a validated pig incisional pain model using von Frey methodology, the study ensures reliability and effectiveness of results, laying a solid foundation for subsequent clinical trials.
- Broad Market Prospects: With increasing healthcare system demands to reduce opioid reliance, the successful development and approval of PRF-110 could open new growth opportunities for PRF Technologies in the postoperative pain management market, enhancing its competitive edge.
See More
PRF Technologies Receives FDA Clearance for OcuRing™-K Clinical Trial
- FDA Milestone: PRF Technologies' OcuRing™-K has received IND clearance from the FDA, marking a significant advancement in the company's ophthalmic drug delivery strategy, with plans to initiate a multi-center Phase II clinical trial in the second half of 2026 to evaluate pain reduction and inflammation control.
- Innovative Treatment: OcuRing™-K is a bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application, potentially eliminating the need for complex post-surgical eye drop regimens, thereby simplifying patient recovery and improving treatment consistency.
- Addressing Market Needs: Cataract surgery is one of the most commonly performed procedures globally, and PRF Technologies' OcuRing™-K aims to enhance drug delivery consistency and reduce dosing burdens, which could significantly improve patient adherence to post-operative care.
- Strategic Platform Expansion: Through its majority ownership of LayerBio, PRF Technologies is building a differentiated ophthalmic platform that may support various applications, including other NSAIDs, steroids, and anti-VEGF products, thereby enhancing the company's long-term value proposition in the healthcare sector.
See More
PainReform Reports Significant Reduction in FY 2025 Net Loss
- Net Loss Reduction: PainReform reported a net loss of approximately $4.8 million for FY 2025, significantly down from $14.6 million in FY 2024, indicating positive progress in cost control and operational efficiency.
- Cash Position: As of December 31, 2025, PainReform held approximately $4.1 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operations and growth initiatives.
- Financial Income Growth: The financial income for FY 2025 was $108,000, up from approximately $93,000 in FY 2024, reflecting improvements in investment returns that may lay the groundwork for future profitability.
- Future Outlook: With the reduction in net loss and improved cash flow, PainReform is positioned for better financial performance in the future, enhancing investor confidence and supporting potential business expansion.
See More
PRF Technologies Partners with EDF for Solar Analytics Agreement
- Strategic Partnership: PRF Technologies' DeepSolar unit has signed a solar analytics services agreement with a subsidiary of EDF Group, marking a new phase for its utility-scale solar power plant in Israel and expected to create new commercial revenue opportunities for the company.
- Technical Due Diligence Initiated: Under the agreement, DeepSolar has commenced a technical due diligence engagement, analyzing historical and operational data to support an independent technical review of the solar asset, thereby enhancing transparency and decision-making efficiency in asset management.
- Smart TDD Service Implementation: DeepSolar's Smart TDD service is designed to support multiple use cases across the solar asset lifecycle through analytics-driven methodologies, helping clients identify potential defects and optimize asset performance during acquisition and performance assessments.
- Growing Market Demand: PRF Technologies' Chairman Ehud Geller noted that the increasing demand for technical due diligence and analytics services among large solar operators illustrates the growing commercial interest in DeepSolar's offerings, indicating significant growth potential for the company in the renewable energy sector.
See More
